Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06032923 · ClinicalTrials.gov registry record · Phase 1

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

A Phase 1 study of Systemic Lupus Erythematosus (SLE), sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
1
Study location

NCT06032923 is a Phase 1 study of Systemic Lupus Erythematosus (SLE) that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 78 participants, below the 1,059-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06032923, a Phase 1 study of Systemic Lupus Erythematosus (SLE), is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinucleotide (NAD)+ boosting with nicotinamide riboside blunts type 1 IFN activation in-vivo in monocytes of healthy subjects and ex-vivo in SLE subjects. These findings support the proposal of the hypothesis that NAD+ boosting by NR supplementation will modulate metabolic pathways in lupus and blunt type 1 interferon signaling. Moreover, as type 1 interferon drives endothelial dysfunction, linked to increased cardiovascular risk, the effect of NR on endothelial function will be examined. Objectives: Primary Objective: Evaluate the effect of NR vs. placebo on immunometabolic and inflammatory remodeling in female SLE subjects: Exploratory Objective: Compare and characterize myeloid cell bioenergetic and immunometabolic profiles in healthy control and SLE female subjects Endpoints: Primary Endpoint: The primary end point will be to assess the effect of NR on blunting type I IFN signaling by measuring monocytic secretion of IFN-beta secretion compared to baseline in response to placebo vs. NR supplemented in SLE study subjects. Exploratory Endpoints: Healthy control vs. SLE subjects: * Compare type I IFN transcript profiles in monocytes and neutrophils at baseline and in response to activation. * Assess cell bioenergetics including: 1) monocyte and neutrophil metabolic flux mass spectroscopy of 13C-glucose and 13Cglutamine analysis to investigate their metabolic fates; (iii) Mitochondrial oxygen consumption (using glucose, amino acid, and fatty acid substrates) and glycolysis rates. SLE baseline vs. NR/placebo supplementation: Baseline vs. 6 weeks of NR/placebo: -Assess effect of NR on bioenergetics by measuring steady-state metabolite levels comparing changes in plac

Interventions

  • DIETARY_SUPPLEMENT Nicotinamide Riboside

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-03-13
Est. Completion 2028-08-01
Phase Phase 1

What the Registry Record Tells You About NCT06032923

The ClinicalTrials.gov registry entry for NCT06032923 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,059-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (93% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide Riboside is the first listed.

NCT06032923 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT06032923 about?

NCT06032923 is a clinical study titled "Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus". Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinuc...

What is the current status of trial NCT06032923?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-03-13. Estimated completion is 2028-08-01.

What conditions does trial NCT06032923 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE).

What interventions are being tested in trial NCT06032923?

The interventions under investigation include: Nicotinamide Riboside (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06032923?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06032923 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus (SLE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.